Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 523 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Allergan Clear all
Completed Phase 3 Interventional

Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension

NCT00332072
View directory record Official record
Conditions
Ocular Hypertension
Interventions
bimatoprost/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Ogden, Utah
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Not applicable Interventional Results available

A Safety and Effectiveness Study of JUVÉDERM VOLBELLA® XC Injectable Gel for Lip and Perioral Enhancement

NCT01998581
View directory record Official record
Conditions
Subjects Desiring Lip Augmentation
Interventions
JUVEDERM VOLBELLA® XC, Restylane-L®
Device
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema

NCT00464685
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone, Sham injection, Laser Photocoagulation
Drug · Procedure
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of a New Treatment for Diabetic Macular Edema

NCT00168389
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone, Sham
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Inglewood, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of Style 410 Silicone-Filled Breast Implant Study

NCT00690339
View directory record Official record
Conditions
Breast Augmentation, Breast Reconstruction, Revision of Augmentation or Reconstruction
Interventions
Style 410 Silicone-Filled Breast Implants
Device
Lead sponsor
Allergan Medical
Industry
Eligibility
18 Years and older · Female only
Enrollment
941 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 16, 2026, 5:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Perception of Facial Expression in Subjects With and Without Crow's Feet Lines

NCT02417077
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Photographic Review
Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
393 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Saratoga Springs, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia

NCT03857542
View directory record Official record
Conditions
Presbyopia
Interventions
Pilocarpine HCl Ophthalmic Solution, Vehicle
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 55 Years
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
35
States / cities
Dothan, Alabama • Prescott, Arizona • Sun City, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease

NCT03226769
View directory record Official record
Conditions
Meibomian Glands, Dry Eye Syndromes
Interventions
TrueTear™, Thermalon Dry Eye Compress
Device
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 16, 2026, 5:27 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Tear Osmolarity Over Time With Artificial Tears

NCT01227226
View directory record Official record
Conditions
Dry Eye
Interventions
Artificial tears
Drug
Lead sponsor
Hom, Milton M., OD, FAAO
Individual
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Oct 16, 2026, 5:27 PM EDT
Completed No phase listed Observational

Histological and Microbiological Evaluation of Late Occurring Nodules With Hyaluronic Acid Dermal Fillers

NCT03425721
View directory record Official record
Conditions
Dermal Nodule
Interventions
No Intervention
Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
West Hollywood, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00332384
View directory record Official record
Conditions
Ocular Hypertension
Interventions
brimonidine/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Phase 4 Interventional

TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema

NCT01870440
View directory record Official record
Conditions
Macular Edema, Uveitis
Interventions
Ozurdex Intravitreal Injection (0.7 mg)
Drug
Lead sponsor
Northern California Retina Vitreous Associates
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Phase 4 Interventional Results available

Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NCT03233438
View directory record Official record
Conditions
Bacterial Infections, Acute Bacterial Skin and Skin Structure Infection
Interventions
Dalbavancin, Usual Care
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia

NCT00894517
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Botulinum Toxin Type A, Placebo (saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
45 Years to 70 Years · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Phase 2 Interventional Results available

A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines

NCT05152576
View directory record Official record
Conditions
Forehead Lines
Interventions
OnabotulinumtoxinA X, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Newport Beach, California • Mount Kisco, New York • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 16, 2026, 5:27 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Botulinum Toxin Type A for Cold Intolerance Secondary to Digital Amputations and Replantations: A Pilot Study

NCT04917731
View directory record Official record
Conditions
Cold Intolerance
Interventions
Botulinum toxin type A
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Phase 4 Interventional Results available

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

NCT01170884
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Phase 2 Interventional Results available

AGN-199201 for the Treatment of Erythema With Rosacea

NCT01735201
View directory record Official record
Conditions
Rosacea, Erythema
Interventions
AGN-199201 Dose A, AGN-199201 Dose B, AGN-199201 Dose C, AGN-199201 Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Not applicable Interventional

Study to Evaluate Efficacy and Tolerability of Two Topical Regimens in Subjects With Moderate to Severe Facial Photodamage Who Have Received Cosmetic Injections

NCT03559972
View directory record Official record
Conditions
Facial Photodamage
Interventions
on-label facial injection
Other
Lead sponsor
Allergan
Industry
Eligibility
30 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
San Diego, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Phase 2Phase 3 Interventional

A Multi-Center Randomized Study to Evaluate the Efficacy and Safety of an Investigational Lubricant Eye Drop

NCT00243711
View directory record Official record
Conditions
Dry Eye
Interventions
Carboxymethylcellulose sodium and Glycerin
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Warrensburg, Missouri
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo

NCT01387906
View directory record Official record
Conditions
Hypotrichosis
Interventions
topical bimatoprost
Drug
Lead sponsor
Kenneth Beer
Individual
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2012 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Not applicable Interventional Results available

Safety and Tolerability of Artificial Tears in Dry Eye Subjects

NCT00932477
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Glycerin and Polysorbate 80 based artificial tear
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 16, 2026, 5:27 PM EDT
Completed No phase listed Observational

Anatomic Outcomes Following Ozurdex Injections

NCT01282411
View directory record Official record
Conditions
Retinal Vein Occlusions
Interventions
Not listed
Lead sponsor
Barnes Retina Institute
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 16, 2026, 5:27 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

NCT02959983
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
76
States / cities
Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 16, 2026, 5:27 PM EDT